1-(3-methyl-quinoxalin-2-yl)piperazine | 50693-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-methyl-quinoxalin-2-yl)piperazine
• 英文别名: 2-Methyl-3-piperazin-1-yl-quinoxaline；2-Methyl-3-(piperazin-1-yl)quinoxaline；2-methyl-3-piperazin-1-ylquinoxaline
• CAS: 50693-76-0
• 化学式: C₁₃H₁₆N₄
• mdl: MFCD01127760
• 分子量: 228.297
• InChiKey: IPWZRMZLVSDBKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-methyl-quinoxalin-2-yl)piperazine 在 lithium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (R)-1-{4-[4-(3-Methyl-quinoxalin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-ethanol
  参考文献：
  名称：

  Orally-Effective, Long-Acting Sorbitol Dehydrogenase Inhibitors:  Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Novel Heterocycle-Substituted Piperazino-Pyrimidines

  摘要：

  Optimization of a previously disclosed sorbitol dehydrogenase inhibitor (SDI, II) for potency and duration of action was achieved by replacing the metabolically labile N,N-dimethylsulfamoyl group with a variety of heterocycles. Specifically, this effort led to a series of novel, in vitro potent SDIs with longer serum half-lives and acceptable in vivo activity in acutely diabetic rats (e.g., 62, 67, and 69). However, the desired in vivo potency in chronically diabetic rats, ED90 less than or equal to 5 mg/kg/day, was achieved only through further modification of the piperazine linker. Several members of this family, including 86, showed better than the targeted potency with ED90 values of 1-2 mg/kg/day. Compound 86 was further profiled and found to be a selective inhibitor of sorbitol dehydrogenase, with excellent pharmacodynamic/pharmacokinetic properties, demonstrating normalization of sciatic nerve fructose in a chronically diabetic rat model for similar to17 h, when administered orally at a single dose of 2 mg/kg/day.

  DOI：

  10.1021/jm010440g
• 作为产物：
  描述：

  2-methyl-3-[4-(phenylmethyl)piperazin-1-yl]quinoxaline 在 palladium 10% on activated carbon 甲酸铵 作用下， 以 甲醇 为溶剂， 以38%的产率得到1-(3-methyl-quinoxalin-2-yl)piperazine
  参考文献：
  名称：

  [EN] ANTIPARASITIC TERPENE ALKALOIDS
  [FR] TERPENE ALCALOIDES ANTIPARASITIQUES

  摘要：

  公开号：

  WO2004072086A3

文献信息

• Antiparasitic terpene alkaloids
  申请人：Chubb A. Nathan

  公开号：US20070185101A1

  公开（公告）日：2007-08-09

  The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an, antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

  本发明涉及新型萜类生物碱及其作为抗寄生虫剂的用途。本发明还涉及一种抗寄生虫剂，其包含本发明中的萜类生物碱化合物作为抗寄生虫制剂中的有效成分。更具体地，本发明涉及萜类生物碱（1S，2R，4aS，5R，8R，8aR）-2-（乙酰氧基）-8a-羟基-3，8-二甲基-5-（1-甲基乙烯基）-1,2,4a,5,6,7,8,8a-八氢萘-1-基（2S，3aR，9bR）-6-氯-9b-羟基-5-甲基-1,2,3,3a,5,9b-六氢吡咯[2,3-c] [2,1]苯并噁唑-2-羧酸酯的衍生物。还公开了包含该物质的药物组合物。
• ANTIPARASITIC TERPENE ALKALOIDS
  申请人：Pfizer Limited

  公开号：EP1597264A2

  公开（公告）日：2005-11-23
• US6548499B1
  申请人：——

  公开号：US6548499B1

  公开（公告）日：2003-04-15
• US7494992B2
  申请人：——

  公开号：US7494992B2

  公开（公告）日：2009-02-24
• [EN] SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE QUINOXALINE SUBSTITUES UTILISES COMME ANTAGONISTES DU RECEPTEUR DE L'INTERLEUKINE-8
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1999042461A1

  公开（公告）日：1999-08-26

  (EN) Quinoxaline compounds are described as well as method for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as, a chemokine-mediated disease selected from psoriasis, or atopic dermatitis, disease associated with pathological angiogenesis (i.e. cancer), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, or allograft rejections.(FR) Cette invention se rapporte à des composés de quinoxaline, ainsi qu'à des procédés de préparation de ces composés et à des compositions pharmaceutiques contenant ces composés, qui servent comme antagonistes du récepteur de l'interleukine-8 (IL-8) et qui peuvent être utilisés dans le traitement des maladies induites par la chémokine, dans lesquelles la chémokine se fixe à un récepteur d'IL-8a (CXCR1) ou b (CXCR2), telles que des maladies induites par la chémokine choisies parmi le psoriasis ou la dermatite atopique, les maladies associées à une angiogenèse pathologique (par exemple le cancer), l'asthme, les broncho-pneumopathies chroniques obstructives, le syndrome de détresse respiratoire chez l'adulte, l'arthrite, les infections intestinales inflammatoires, la maladie de Crohn, la colite ulcéreuse, l'ulcère gastrique, le choc septique, le choc endotoxique, les septicémies à germes Gram négatif, le syndrome du choc toxique staphylococcique, les attaques, les lésions de reperfusion cardiaque et rénale, la glomérulonéphrite ou les thromboses, la maladie d'Alzheimer, les réactions du greffon contre l'hôte ou les rejets d'allogreffes.